Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (888) 282-7099 Click to print page  Print

Browse Trials


In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.


Currently viewing trials
(Last updated: May 21, 2022)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

Brain Mets

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Leptomeningeal Disease

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

1

NEAREST SITE: 339 miles
The Angeles Clinic and Research Institute
Los Angeles,CA

VISITS: May require hospitalization

PHASE: I

NCT ID: NCT04025216

CAR-T Immunotherapy for Metastatic Triple Negative & ER-Low, HER2- Breast Cancer that is TnMUC1-Positive

A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma Scientific Title

Purpose
To study the safety, best dose, side effects (good and bad), and anti-cancer activity of a new CAR-T cell immunotherapy that targets cancer cells that test positive for MUC1.
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer that tests positive for the antigen TnMUC1.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®) and fludarabine (Fludara®), by IV, once, before the CART-<span class="highlight">T</span> immunotherapy is given</li> <li class="seamTextUnorderedListItem">CART-<span class="highlight">TnMUC1</span>, by IV, once</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. May require hospital stay.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that <span class="highlight">tests</span> positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This <span class="highlight">trial</span> is enrolling people with <span class="highlight">triple</span> negative as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem"><span class="highlight">CAR</span>-<span class="highlight">T</span> is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">The cells are removed from your blood, modified with chimeric antigen receptors (CARs) that allow <span class="highlight">them</span> to attack proteins on cancer cells, and then put back in your body. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span>-<span class="highlight">T</span> <span class="highlight">therapy</span> being used in this study <span class="highlight">trains</span> the immune system to attack MUC1-positive cancer cells. </li> <li class="seamTextUnorderedListItem">Before you have the <span class="highlight">CAR</span>-<span class="highlight">T</span> cell <span class="highlight">therapy</span>, you will be given the chemotherapy drugs fludarabine and cyclophosphamide. These drugs are given to prepare your immune system to receive the <span class="highlight">CAR</span>-<span class="highlight">T</span> cells. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other <span class="highlight">types</span> of cancers that <span class="highlight">test</span> <span class="highlight">TnMUC1</span>-positive.</li> <li class="seamTextUnorderedListItem"><span class="highlight">Targets</span> or mutations: <span class="highlight">TnMUC1</span></li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04025216' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy' target='_blank'>NCI Dictionary of Cancer Terms: CAR T-cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/faq-about-car-t-cell-therapy/' target='_blank'>Dana-Farber Cancer Institute: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tmunity.com/pipeline' target='_blank'>Drug Company Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/MUC1' target='_blank'>Wikipedia: MUC1</a> </li></ul>
See more
2

NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte,CA

VISITS: May require hospitalization

PHASE: I

NCT ID: NCT03696030

CAR T-Cell Immunotherapy in HER2+ Breast Cancer with Brain or Leptomeningeal Metastases

A Phase 1 Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and/or Leptomeningeal Metastases From HER2 Positive Cancers Scientific Title

Purpose
To study the safety, best dose, and effects (good and bad) of a CAR T-cell immunotherapy that is delivered directly into the brain.
Who is this for?
People with metastatic (stage IV) HER2 positive (HER2+) breast cancer with brain or leptomeningeal metastases.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw to collect white blood cells to make your HER2 <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> (leukapheresis)</li> <li class="seamTextUnorderedListItem">Surgery to place a device (similar to a chemotherapy port) under your scalp</li> <li class="seamTextUnorderedListItem">HER2 <span class="highlight">CAR</span> <span class="highlight">T</span>-cells, by injection, weekly, 3 <span class="highlight">times</span></li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i> </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Follow up</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Every 2 months for 1 year, then every year for 15 years</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leptomeningeal metastases are when cancer spreads to the membranes surrounding the brain and/or the spinal cord (leptomeninges) or to the cerebrospinal fluid.</li> <li class="seamTextUnorderedListItem"><span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">Your blood cells are removed and modified in a lab with chimeric antigen receptors (CARs) so that they can attack a specific protein.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span>-cells are then infused back into you while you are hospitalized. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> being used in this study <span class="highlight">trains</span> the immune system to attack HER2+ cancer cells.</li> <li class="seamTextUnorderedListItem">You will have surgery to insert a device under your scalp so that the <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> can be infused directly into your brain.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03696030' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cityofhope.org/physician-news/breast-cancer-car-t-cell-therapy' target='_blank'>City of Hope Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy' target='_blank'>NCI Dictionary of Cancer Terms: CAR T-cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html' target='_blank'>American Cancer Society: CAR T-cell Therapy and Its Side Effects</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Leukapheresis' target='_blank'>Wikipedia: Leukapheresis</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/brain-mets/' target='_blank'>Metastatic Breast Cancer Network: Brain Metastases</a> </li></ul>
See more
3

NEAREST SITE: 353 miles
City of Hope National Medical Center
Duarte,CA

VISITS: May require hospital stay

PHASE: I

NCT ID: NCT04650451

Experimental CAR T-Cell Immunotherapy BPX-603 for Advanced HER2 Positive Breast Cancer

A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors Scientific Title

Purpose
To study the safety, best dose and effects (good and bad) of an experimental CAR T-cell immunotherapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have no standard of care treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BPX-603 (<span class="highlight">CAR</span> <span class="highlight">T</span>-cell immunotherapy), by IV, one <span class="highlight">time</span></li> <li class="seamTextUnorderedListItem">Rimiducid, by IV, weekly</li> <li class="seamTextUnorderedListItem">You may also receive, <span class="highlight">temsirolimus</span>, by IV, one <span class="highlight">time</span></li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BPX-603 is the experimental <span class="highlight">CAR</span> <span class="highlight">T</span>-cell immunotherapy used in this <span class="highlight">trial</span>.</li> <li class="seamTextUnorderedListItem"><span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">Your blood cells are removed and modified in a lab with chimeric antigen receptors (CARs) so that they can attack a specific protein.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span>-cells are then infused back into you while you are hospitalized.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> being used in this study <span class="highlight">trains</span> the immune system to attack HER2+ cancer cells.</li> <li class="seamTextUnorderedListItem">This <span class="highlight">trial</span> is also enrolling people with other <span class="highlight">types</span> of HER2 positive cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04650451' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy' target='_blank'>NCI Dictionary of Cancer Terms: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html' target='_blank'>American Cancer Society: CAR T-cell Therapy and Its Side Effects</a> </li></ul>
See more
4

NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte,CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04020575

CAR T-Cell Immunotherapy for Metastatic Breast Cancer That Tests Positive for MUC 1*

Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 Specific for a Cleaved Form of MUC1 (MUC1*) Scientific Title

Purpose
To look at the safety, best dose and effects of an experimental CAR T-cell immunotherapy that targets cancer cells that test positive for MUC1*, a special type of the MUC1 protein.
Who is this for?
People with metastatic (stage IV) breast cancer that tests positive for MUC1 and who have already received at least one standard therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw to collect white blood cells to make your personalized <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> (leukapheresis)</li> <li class="seamTextUnorderedListItem">Chemotherapy to deplete your lymph cells</li> <li class="seamTextUnorderedListItem">huMNC2-CAR44 <span class="highlight">CAR</span> <span class="highlight">T</span>-cells, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells. </li> <li class="seamTextUnorderedListItem">Your blood cells are removed and modified in a lab with chimeric antigen receptors (CARs) so that they can attack a specific protein. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span>-cells are then infused back into you while you are hospitalized </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> being used in this study <span class="highlight">trains</span> the immune system to attack MUC1 on cancer cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04020575' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html' target='_blank'>MD Anderson Cancer Center: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/research/car-t-cells' target='_blank'>NCI: Car T-Cells</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.minervabio.com/clinical-trial-humnc2-car44-in-mbc/' target='_blank'>Minerva Biotechnologies: Study Page</a> </li></ul>
See more
5

NEAREST SITE: 353 miles
City of Hope National Medical Center
Duarte,CA

VISITS: 10 visits over 13 months, may require 1 hospital stay

PHASE: I

NCT ID: NCT04660929

CAR Immunotherapy for Advanced HER2 Positive Breast Cancer

A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors Scientific Title

Purpose
To study the safety, side effects and anti-cancer activity of the experimental CAR immunotherapy CT-0508.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have no standard treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw to collect white blood cells to make your personalized <span class="highlight">CAR</span> <span class="highlight">therapy</span> (leukapheresis)</li> <li class="seamTextUnorderedListItem">CT-0508, by IV, 1 or 3 <span class="highlight">times</span>, over 1 week</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CT-0508 is a <span class="highlight">CAR</span> immunotherapy made from your own immune cells. </li> <li class="seamTextUnorderedListItem">First, your immune cells are removed from your body during a process called leukapheresis. </li> <li class="seamTextUnorderedListItem">Then the immune cells are modified with chimeric antigen receptors (CARs) so they can attack HER2 proteins on cancer cells.</li> <li class="seamTextUnorderedListItem">Finally, the modified immune cells are then infused back into your body. This part of the <span class="highlight">trial</span> may include a hospital stay. </li> <li class="seamTextUnorderedListItem">This <span class="highlight">trial</span> is also enrolling people with other <span class="highlight">types</span> of HER2 positive cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04660929' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://carismatx.com/science/' target='_blank'>Carisma Therapeutics Drug Information Page: CT-0508</a> </li></ul>
See more
6

NEAREST SITE: 948 miles
Sarah Cannon Research Institute at HealthONE
Denver,CO

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT05239143

P-MUC1C-ALLO1 CAR-T Cell Immunotherapy for Advanced Breast Cancer

A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors Scientific Title

Purpose
To study the safety, best dose, effects (good and bad), and anti-cancer activity of P-MUC1C-ALLO1, an experimental CAR-T cell immunotherapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that has progressed on standard treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups based on when you enroll: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">P-MUC1C-ALLO1 <span class="highlight">CAR</span>-<span class="highlight">T</span> cell immunotherapy, by IV, 1 session</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">P-MUC1C-ALLO1 <span class="highlight">CAR</span>-<span class="highlight">T</span> cell immunotherapy, by IV, multiple sessions</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">May require 1 biopsy</li> <li class="seamTextUnorderedListItem">Rimiducid (CaspaCIDe®) may be given for safety</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">P-MUC1C-ALLO1 is an experimental immunotherapy called <span class="highlight">CAR</span>-<span class="highlight">T</span> cell <span class="highlight">therapy</span>.</li> <li class="seamTextUnorderedListItem">Allogeneic <span class="highlight">CAR</span>-<span class="highlight">T</span> cell <span class="highlight">therapy</span> is an immunotherapy made from donor immune cells.</li> <li class="seamTextUnorderedListItem">Donor immune cells are modified with chimeric antigen receptors (CARs) so they can attack cancer cells.</li> <li class="seamTextUnorderedListItem">Rimiducid (CaspaCIDe®) is an enzyme that can be administered for safety to kill <span class="highlight">CAR</span>-<span class="highlight">T</span> cells, if needed.</li> <li class="seamTextUnorderedListItem">This <span class="highlight">trial</span> is also enrolling people with other <span class="highlight">types</span> of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05239143' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://poseida.com/science/pipeline/#cart-therapies' target='_blank'>Poseida Therapeutics Drug Information Page: P-MUC1C-ALLO1</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-p-muc1c-allo1-a-fully-allogeneic-car-t-targeting-multiple-solid-tumors-301447910.html' target='_blank'>Poseida Therapeutics Press Release: P-MUC1C-ALLO1</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bellicum.com/caspacide-safety-switch/' target='_blank'>Bellicum Phamaceuticals Drug Information Page: Rimiducid (CaspaCIDe®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.frontiersin.org/articles/10.3389/fimmu.2020.618427/full' target='_blank'>Journal Article: Allogeneic CAR T-Cell Immunotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li></ul>
See more
7

NEAREST SITE: 1643 miles
Texas Children's Hospital
Houston,TX

VISITS: Hospital stay may be required

PHASE: I

NCT ID: NCT03635632

CAR T-Cell Therapy for Advanced Breast Cancer That Tests Positive for GD2

Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers (GAIL-N) Scientific Title

Purpose
To study the safety, best dose, anti-cancer activity and side effects (good and bad) of a new CAR-T cell immunotherapy that targets cancer cells that test positive for GD2.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that tests positive for GD2 and who have already received at least two therapies for advanced disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw to collect white blood cells to make your personalized <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> (leukapheresis)</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®) and fludarabine (Fludara®), by IV, at least 24 hours before the <span class="highlight">CAR</span> <span class="highlight">T</span>-cell immunotherapy is given</li> <li class="seamTextUnorderedListItem">C7R-GD2 <span class="highlight">CAR</span> <span class="highlight">T</span>-cell immunotherapy, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells. The white blood cells are removed from your body and then modified with chimeric antigen receptors (CARs) so they can attack specific proteins. These white blood cells are then infused into your body. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> used in this study <span class="highlight">trains</span> the immune system to attack cancer cells that <span class="highlight">test</span> positive for the protein GD2.</li> <li class="seamTextUnorderedListItem">You will receive the chemotherapy drugs cyclophosphamide (Cytoxan®) and fludarabine (Fludara®) before you receive the <span class="highlight">CAR</span> <span class="highlight">T</span>-cells. This makes it easier for the <span class="highlight">CAR</span> <span class="highlight">T</span>-cells to get into your immune system. </li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other <span class="highlight">types</span> of advanced cancer.</li> <li class="seamTextUnorderedListItem"><span class="highlight">Targets</span> or mutations: GD2</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03635632' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcm.edu/research/clinical-trials/h-42207' target='_blank'>Baylor College of Medicine Study Page: GAIL-N</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy' target='_blank'>NCI Dictionary of Cancer Terms: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html' target='_blank'>MD Anderson Cancer Center: T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458232/' target='_blank'>Journal Article: GD2 Expression in Breast Cancer</a> </li></ul>
See more
8

NEAREST SITE: 1643 miles
Houston Methodist Hospital
Houston,TX

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT02442297

CAR-T Cell Immunotherapy for HER2-Positive Brain Tumors

Phase I Study of Intracranial Injection of T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) in Subjects With HER2-Positive Tumors of the Central Nervous System (iCAR) Scientific Title

Purpose
To study the best dose, side effects, and anti-cancer activity of using HER2 CAR-T cell therapy for treating tumors in the central nervous system (CNS).
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the central nervous system (brain or spinal cord).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> plan. Hospital stay may be required.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The HER2 antibody used in this study is attached to <span class="highlight">T</span> cells. </li> <li class="seamTextUnorderedListItem"><span class="highlight">T</span> cells, also called <span class="highlight">T</span> lymphocytes, are special infection-fighting immune cells present in the blood that can kill other cells, including <span class="highlight">tumor</span> cells. </li> <li class="seamTextUnorderedListItem">When the HER2 antibody is joined to a <span class="highlight">T</span> cell it is called a chimeric antigen receptor (<span class="highlight">CAR</span>) which can <span class="highlight">target</span> HER2-positive <span class="highlight">tumor</span> cells.</li> <li class="seamTextUnorderedListItem">These HER2-<span class="highlight">CAR</span> <span class="highlight">T</span> cells are an investigational product not approved by the Food and Drug Administration.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02442297' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li></ul>
See more
9

NEAREST SITE: 1643 miles
Baylor St. Luke's Medical Center
Houston,TX

VISITS: May require hospital stay

PHASE: I

NCT ID: NCT03740256

CAR-T Cell Immunotherapy & Immunotherapy Injected Directly into Tumors for Metastatic HER2 Positive Breast Cancer

A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors Scientific Title

Purpose
To study the safety, anti-cancer activity and other effects (good and bad) of giving a HER2-specific CAR-T Cell immunotherapy and an immunotherapy injected directly into a tumor.
Who is this for?
People with metastatic (stage IV) HER2 positive (HER2+) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CAdVEC, by injection directly into a <span class="highlight">tumor</span>, one <span class="highlight">time</span></li> </ul> <p class="seamTextPara"> followed by </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HER2-specific <span class="highlight">CAR</span>-<span class="highlight">T</span> Cell <span class="highlight">therapy</span>, by IV, one <span class="highlight">time</span></li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">CAR</span>-<span class="highlight">T</span> is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">The cells are removed from your blood, modified with chimeric antigen receptors (CARs) that allow <span class="highlight">them</span> to attack proteins on cancer cells, and then put back in your body.</li> <li class="seamTextUnorderedListItem">CAdVEC is an oncolytic adenovirus--this means it <span class="highlight">targets</span> and kills cancer cells. It may directly kill cancer cells and stimulate your immune system to go after and kill cancer cells.</li> <li class="seamTextUnorderedListItem">CAdVEC is injected directly into a <span class="highlight">tumor</span>. </li> <li class="seamTextUnorderedListItem">This <span class="highlight">trial</span> is also enrolling people with other <span class="highlight">types</span> of HER2 positive cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03740256' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li><li class='seamTextUnorderedListItem'><a href='https://ncit.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=20.07d&code=C158743&ns=ncit&type=all&key=null&b=1&n=0&vse=null' target='_blank'>NCI Thesaurus: CAdVEC</a> </li></ul>
See more
10

NEAREST SITE: 1959 miles
Sarah Cannon Research Institute and Tennessee Oncology
Nashville,TN

VISITS: Hospital stay may be required

PHASE: I

NCT ID: NCT05274451

LYL797 CAR T-Cell Immunotherapy for Triple Negative, ROR1 Positive Advanced Breast Cancer

A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies Scientific Title

Purpose
To study the safety, best dose, effects (good and bad), and anti-cancer activity of LYL797, an experimental type of immunotherapy called CAR T-cell therapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-), ROR1 positive breast cancer that has progressed on standard treatment. You must not have received T-cell therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LYL797 <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span></li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Requires 1 biopsy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LYL797 is an experimental <span class="highlight">type</span> of immunotherapy called <span class="highlight">CAR</span> <span class="highlight">T</span>-cell/<span class="highlight">CAR</span>-<span class="highlight">T</span> <span class="highlight">therapy</span>.</li> <li class="seamTextUnorderedListItem"><span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">The cells are removed from your blood, modified with chimeric antigen receptors (CARs) that allow <span class="highlight">them</span> to attack proteins on cancer cells, and then put back in your body.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> being used in this study <span class="highlight">trains</span> the immune system to attack ROR1 positive cancer cells</li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other <span class="highlight">types</span> of ROR1 positive cancers.</li> <li class="seamTextUnorderedListItem"><span class="highlight">Targets</span> or mutations: ROR1</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05274451' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://lyell.com/our-pipeline' target='_blank'>Lyell Immunopharma Drug Information Page: LYL797</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/faq-about-car-t-cell-therapy/' target='_blank'>Dana-Farber Cancer Institute: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy#section-adoptive-cell-therapy' target='_blank'>Breastcancer.org: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li></ul>
See more
11

NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD

VISITS: Hospital stay for at least 1 week; follow-up visits for 2 years

PHASE: I-II

NCT ID: NCT02830724

CAR T-Cell Immunotherapy for Metastatic Breast Cancer That Tests Positive for CD70

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70 Expressing Cancers Scientific Title

Purpose
To study the safety and effects (good and bad) of using a new type of CAR T-cell immunotherapy.
Who is this for?
People with metastatic (stage IV) breast cancer that tests positive for CD70 who have already received at least one standard therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Hospital stay (at least 1-week):</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leukapheresis (blood draw for the collection of cells)</li> <li class="seamTextUnorderedListItem">Cyclophosphamide, by IV, once a day, for 2 days</li> <li class="seamTextUnorderedListItem">Fludarabine, by IV, once a day, for 5 days</li> <li class="seamTextUnorderedListItem">Aldesleukin, by IV, 3 <span class="highlight">times</span> a day, for 3 days</li> <li class="seamTextUnorderedListItem">Anti-hCD70 <span class="highlight">CAR</span> <span class="highlight">T</span>-cells, by IV, one <span class="highlight">time</span></li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Post-hospital stay:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Antibiotic for 6 months</li> <li class="seamTextUnorderedListItem">Repeat Leukapheresis (blood draw for the collection of cells)</li> <li class="seamTextUnorderedListItem">1-2 day hospital visits (for lab <span class="highlight">tests</span>, imaging studies, and a physical exam), every 1-3 months for the 1st year after <span class="highlight">treatment</span>, every 6 months for the 2nd year, and then as determined by your doctor</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">CAR</span> <span class="highlight">T</span>-cell is a personalized immunotherapy made from your white blood cells. </li> <li class="seamTextUnorderedListItem">After your blood cells are removed, they are modified with chimeric antigen receptors (CARs) so they can attack specific proteins. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span>-cells are then infused back into you while you are hospitalized. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span> used in this study is designed to get the immune system to see and kill cancer cells that are CD70+. </li> <li class="seamTextUnorderedListItem">Along with the <span class="highlight">CAR</span>-<span class="highlight">T</span> immunotherapy, you will receive the chemotherapy drugs fludarabine and cyclophosphamide. These drugs are given to deplete the lymph cells. </li> <li class="seamTextUnorderedListItem">You will also receive aldesleukin, a drug that stimulates the growth and development of <span class="highlight">T</span> cells.</li> <li class="seamTextUnorderedListItem"><span class="highlight">Targets</span> or mutations: CD70</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02830724' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.drsusanloveresearch.org/videos/chimeric-antigen-receptor-t-cell-car-t-therapy' target='_blank'>Dr Susan Love Research Foundation: CAR-T Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/25368676' target='_blank'>Journal Article Abstract: CD70, A Potential Target in Breast Cancer?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/search?contains=false&q=Aldesleukin' target='_blank'>NCI Drug Dictionary: Aldesleukin</a> </li></ul>
See more
12

NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD

VISITS: Hospital stay for 4-5 weeks

PHASE: II

NCT ID: NCT04102436

CAR T-Cell Immunotherapy for Metastatic Breast Cancer

A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer Scientific Title

Purpose
To study if an immunotherapy, made from your own white blood cells that are then modified with T-cell receptors, can cause breast cancer tumors to shrink.
Who is this for?
People with metastatic breast cancer that did not respond to the first treatment received.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be in the hospital and receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Before hospital stay:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw for the collection of cells (leukapheresis)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Hospital stay for receiving <span class="highlight">treatment</span> (4-5 weeks):</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Modified white blood cells (<span class="highlight">CAR</span> <span class="highlight">T</span>-cell immunotherapy), by IV</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®) and Fludarabine (Fludara®), by IV</li> <li class="seamTextUnorderedListItem">Aldesleukin, by IV, once every 8 hours, for up to 10 doses</li> <li class="seamTextUnorderedListItem">Antibiotics</li> <li class="seamTextUnorderedListItem">Filgrastim, by injection</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">After hospital stay:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Visits approximately 6 and 12 weeks after <span class="highlight">treatment</span>, then every 3-6 months for 3 years</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">T</span>-cells can be modified in a lab to recognize certain changes in the <span class="highlight">tumor</span>. </li> <li class="seamTextUnorderedListItem">To create the personalized <span class="highlight">T</span> cells, your white blood cells will be collected and modified in ways that will help <span class="highlight">them</span> go after your <span class="highlight">tumor</span> cells. </li> <li class="seamTextUnorderedListItem">These supercharged <span class="highlight">T</span> cells will then be put into your body. This will be done in the hospital. </li> <li class="seamTextUnorderedListItem">This <span class="highlight">type</span> of <span class="highlight">therapy</span> is called <span class="highlight">CAR</span> <span class="highlight">T</span>-cell <span class="highlight">therapy</span>. </li> <li class="seamTextUnorderedListItem">Before you receive the enhanced <span class="highlight">T</span> cells, you will be <span class="highlight">treated</span> with the chemotherapy drugs cyclophosphamide (Cytoxan®) and fludarabine (Fludara®). This is to prepare your body to receive the enhanced <span class="highlight">T</span> cells. </li> <li class="seamTextUnorderedListItem">You will also receive aldesleukin, a drug that enhances immune function and filgrastim, to reduce your risk of developing an infection. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other <span class="highlight">types</span> of metastatic cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04102436' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/research/car-t-cells' target='_blank'>NCI Research Article: CAR T Cells, Engineering Patients’ Immune Cells to Treat Their Cancers</a> </li></ul>
See more